VINC vs. ORMP, CYTT, ADAG, IOBT, LTRN, SGMT, RVPH, ALLK, PRPH, and MCRB
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Oramed Pharmaceuticals (ORMP), Cyteir Therapeutics (CYTT), Adagene (ADAG), IO Biotech (IOBT), Lantern Pharma (LTRN), Sagimet Biosciences (SGMT), Reviva Pharmaceuticals (RVPH), Allakos (ALLK), ProPhase Labs (PRPH), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
Vincerx Pharma has a consensus target price of $5.00, indicating a potential downside of 17.49%. Given Oramed Pharmaceuticals' higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Oramed Pharmaceuticals.
Oramed Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals received 297 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 62.07% of users gave Vincerx Pharma an outperform vote.
Oramed Pharmaceuticals has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 12.0% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Vincerx Pharma had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for Vincerx Pharma and 1 mentions for Oramed Pharmaceuticals. Vincerx Pharma's average media sentiment score of 1.89 beat Oramed Pharmaceuticals' score of 0.57 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Vincerx Pharma has a net margin of 0.00% compared to Vincerx Pharma's net margin of -747.02%. Vincerx Pharma's return on equity of -7.15% beat Oramed Pharmaceuticals' return on equity.
Summary
Oramed Pharmaceuticals beats Vincerx Pharma on 10 of the 16 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vincerx Pharma Competitors List
Related Companies and Tools